BHV-2100 is under clinical development by Biohaven and currently in Phase II for Neuropathic Pain (Neuralgia).

For people suffering from chronic knee pain, especially those over 50, a new treatment is offering hope and relief.

A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

Cellular research indicates that neuropilin-1 plays a crucial role in pain signaling, presenting a potential pathway for ...

Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...

Physical therapy can be effective in treating a condition more than 3 million Americans live with every day: chronic pain.

ANP-390 is under clinical development by AlphaNavi Pharma and currently in Phase I for Peripheral Neuropathic Pain.

NervoVive combines five natural ingredients—Passion Flower, Marshmallow Root, California Poppy Seed, Prickly Pear, and ...

A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in ...